Skip to main content

A PHASE 2, MULTICENTER, MULTI-COHORT, OPEN-LABEL STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE OR POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE AND DARATUMUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Celgene Corporation

Start Date

March 13, 2017

End Date

May 31, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Celgene Corporation

Start Date

March 13, 2017

End Date

May 31, 2022